Please login to the form below
Trobalt
This page shows the latest Trobalt news and features for those working in and with pharma, biotech and healthcare.
GSK/ Valeant's Trobalt set for EU restrictions
European regulatory advisors have recommended GlaxoSmithKline and Valeant's epilepsy drug Trobalt be restricted after safety concerns over its use emerged. ... The CHMP said the move followed cases of abnormal colouring of the skin, nails, lips and eye
Latest news
-
Therapy focus: Epilepsy
In May 2011, GlaxoSmithKline launched its new epilepsy medicine Trobalt in the UK.
-
FDA approves GSK/Valeant anti-seizure drug
In the EU, ezogabine is known as retigabine (Trobalt). The drug received marketing authorisation in the EU in March 2011.
-
GSK launches first-in-class epilepsy drug
GSK introduces Trobalt for the adjunct treatment of adults with partial-onset seizures. ... GlaxoSmithKline (GSK) has launched Trobalt (retigabine), the first in a new class of anti-epileptic drug (AED), for the adjunct treatment of adults with
-
GSK sales fall for first quarter of 2011
Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Country report: The healthcare market in Germany
Committee and the same 'no proof' decision was reached regarding GlaxoSmithKline's Trobalt (retigabine) for epilepsy.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Moderna inks R&D agreements with Vertex and Chiesi
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Could formulary intelligence be your brand differentiator?
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Porterhouse Medical strengthens its senior management team
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Could formulary intelligence be your brand differentiator?
- Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
Quick links
Infographics
